Low-doses Alemtuzumab and Rituximab Combination as First Line Treatment in Aplastic Anemia
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluate efficacy of alemtuzumab and rituximab in aplastic anemia.
Evaluate the hematological response after the administration of alemtuzumab and rituximab
12 months
Yes
David Gomez Almaguer, MD
Principal Investigator
Hospital Universitario Dr. Jose E. Gonzalez
Mexico: Ministry of Health
HE11015
NCT01408342
July 2011
July 2014
Name | Location |
---|